The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 10, 2007

Filed:

Mar. 19, 2001
Applicants:

Magnus Hook, Houston, TX (US);

Yi Xu, Houston, TX (US);

Pietro Speziale, Pavia, IT;

Livia Visal, Rosate, IT;

Fabrizia Casolini, Sondalo, IT;

Joseph M. Patti, Cumming, GA (US);

Pratiksha Patel, Duluth, GA (US);

Paul Domanski, Atlanta, GA (US);

Inventors:

Magnus Hook, Houston, TX (US);

Yi Xu, Houston, TX (US);

Pietro Speziale, Pavia, IT;

Livia Visal, Rosate, IT;

Fabrizia Casolini, Sondalo, IT;

Joseph M. Patti, Cumming, GA (US);

Pratiksha Patel, Duluth, GA (US);

Paul Domanski, Atlanta, GA (US);

Assignees:

Universita Degli Studi di Pavia, Pavia, IT;

The Texas A&M University System, College Station, TX (US);

Inhibitex, Inc., Alpharetta, GA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12P 21/08 (2006.01); C12N 1/00 (2006.01); A61K 39/395 (2006.01); A61K 39/40 (2006.01); C07K 16/12 (2006.01);
U.S. Cl.
CPC ...
Abstract

Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to bothandbacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species. Antibodies generated in this manner have also been shown to exhibit displacement activity and can thus be utilized advantageously in methods wherein these antibodies will be administered to patients having pre-existing staphylococcal infections because of the ability to displace bacterial proteins from binding sites on the extracellular matrix. Finally, a method of identifying, isolating and utilizing displacing antibodies is also provided.


Find Patent Forward Citations

Loading…